Novel MS solutions inspired by MIST

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov.3,711–715 (2004).
  Medline CASGoogle Scholar
• 2  GBI Research. Biomarkers in drug discovery–optimizing drug discovery timeline and costs. GBI Research, CT, USA, 76 (2010).
  Google Scholar
• 3  Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr. Top. Med. Chem.3,1125–1154 (2003).
  MedlineGoogle Scholar
• 4  Bussiere JL. Species selection considerations for preclinical toxicology studies for biotherapeutics. Expert Opin. Drug Metab. Toxicol.4,871–877 (2008).
  Medline CASGoogle Scholar
• 5  Gomase VS, Tagore S. Species scaling and extrapolation. Curr. Drug Metab.9,193–198 (2008).
  Medline CASGoogle Scholar
• 6  Cheng KC, Li C, Uss AS. Prediction of oral drug absorption in humans–from cultured cell lines and experimental animals. Expert Opin. Drug Metab. Toxicol.4,581–590 (2008).
  Medline CASGoogle Scholar
• 7  Ross D, Zhou H. Relationships between metabolic and non-metabolic susceptibility factors in benzene toxicity. Chem.Biol.Interact.184,222–228 (2010).
  Medline CASGoogle Scholar
• 8  Saghir SA, Zhang F, Rick DL, Kan L, Bus JS, Bartels MJ. In vitro metabolism and covalent binding of ethylbenzene to microsomal protein as a possible mechanism of ethylbenzene-induced mouse lung tumorigenesis. Regul. Toxicol. Pharmacol. (2010).
  MedlineGoogle Scholar
• 9  Saha S, New LS, Ho HK, Chui WK, Chan ECY. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol. Lett.192,141–149 (2010).
  Medline CASGoogle Scholar
• 10  Malinowski HJ. The role of in vitro–in vivo correlations (IVIVC) to regulatory agencies. Adv. Exp. Med. Biol.423,261–268 (1997).
  Medline CASGoogle Scholar
• 11  O’Hara T, Hayes S, Davis J, Devane J, Smart T, Dunne A. In vivo–in vitro correlation (IVIVC) modeling incorporating a convolution step. J. Pharmacokinet. Pharmacodyn.28,277–298 (2001).
  MedlineGoogle Scholar
• 12  Anderson S, Luffer-Atlas D, Knadler MP. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol.22,243–256 (2009).▪ Excellent review of in vitro predictability of human excretory and circulating metabolites.
  Medline CASGoogle Scholar
• 13  Dalvie D, Obach RS, Kang P et al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol.22,357–368 (2009).
  Medline CASGoogle Scholar
• 14  Hopfgartner G, Zell M, Q Trap MS. A new tool for metabolite identification. In: Using Mass Spectrometry for Drug Metabolism Studies. CRC Press, Taylor & Francis Group, USA, 277–304 (2005).
  Google Scholar
• 15  Hopfgartner G, Husser C, Zell M. Rapid screening and characterization of drug metabolites using a new quadrupole-linear ion trap mass spectrometer. J. Mass Spectrom.38,138–150 (2003).▪ Excellent review of LC–MS strategies for identification of LC–MS methods to distinguish between C- and N-oxidation metabolites.
  Medline CASGoogle Scholar
• 16  Ramanathan R, Chowdhury SK, Alton KB. Oxidative metabolites of drugs and xenobiotics: LC–MS methods to identify and characterize in biological matrices. In: Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC–MS. Chowdhury, SK (Ed). Elsevier, Amsterdam, The Netherlands, 225–276 (2005).▪ Excellent review of the application of MS in drug discovery and development.
  Google Scholar
• 17  Ramanathan D, LeLacheur RM. Evolving role of mass spectrometry in drug discovery and development. In: Mass Spectrometry in Drug Metabolism and Pharmacokinetics, Ramanathan R (Ed). John Wiley & Sons, Inc., Hoboken, NJ, USA, 1–85 (2008).
  Google Scholar
• 18  Tiller PR, Yu S, Castro-Perez J, Fillgrove KL, Baillie TA. High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a ‘first-line’ approach for metabolite identification studies. Rapid Commun. Mass Spectrom.22,1053–1061 (2008).
  Medline CASGoogle Scholar
• 19  Tiller PR, Yu S, Bateman KP et al. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies. Rapid Commun. Mass Spectrom.22,3510–3516 (2008).
  Medline CASGoogle Scholar
• 20  Ruan Q, Peterman S, Szewc MA et al. An integrated method for metabolite detection and identification using a linear ion trap/orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. J. Mass Spectrom.43,251–261 (2008).▪ Excellent review discussing the application of MS for drug metabolism and pharmacokinetics studies.
  Medline CASGoogle Scholar
• 21  Holcapek M, Kolárová L, Nobilis M. High-performance liquid chromatography–tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites. Anal. Bioanal. Chem.391,59–78 (2008).
  Medline CASGoogle Scholar
• 22  Ramanathan R, Zhong R, Blumenkrantz N, Chowdhury SK, Alton KB. Response normalized liquid chromatography nanospray ionization mass spectrometry. J. Am. Soc. Mass Spectrom.18,1891–1899 (2007).▪ Excellent presentations of the application of a rapid approach to quantitate metabolites, in the absence of reference standards, using LC–MS in conjunction with UV (MetPro).
  Medline CASGoogle Scholar
• 23  Josephs JL, Grubb MF, Yang Y, Humphreys WG. A rapid approach to quantitative in vivo metabolite profiling without the need for authentic standards or labeled compounds. Presented at: 56th ASMS Conference on Mass Spectrometry and Allied Topics, Denver, CO, USA, June 1-5, (2008)
  Google Scholar
• 24  Josephs JL, Grubb MF, Shipkova P, Langish R, Sanders M. A comprehensive strategy for the characterization and optimization of metabolic profiles of compounds using a hybrid linear ion trap/FTMS. Presented at: 53rd ASMS Conference on Mass Spectrometry and Allied Topics. San Antonio, TX, USA, June 2-6, (2005).
  Google Scholar
• 25  Josephs JL, Sanders M. Creation and comparison of MS/MS spectral libraries using quadrupole ion trap and triple-quadrupole mass spectrometers. Rapid Commun. Mass Spectrom.18,743–759 (2004).▪ Excellent papers discussing the time-proportional sample pooling approach.
  Medline CASGoogle Scholar
• 26  Hop CE, Wang Z, Chen Q, Kwei G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J. Pharm. Sci.87,901–3 (1998).
  Medline CASGoogle Scholar
• 27  Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin. Pharmacol. Ther.29,408–413 (1981).
  Medline CASGoogle Scholar
• 28  Jemal M, Xia YQ. The need for adequate chromatographic separation in the quantitative determination of drugs in biological samples by high performance liquid chromatography with tandem mass spectrometry. Rapid Commun. Mass Spectrom.13,97–106 (1999).
  CASGoogle Scholar
• 29  Ramanathan R, Su AD, Alvarez N et al. Liquid chromatography/mass spectrometry methods for distinguishing N-oxides from hydroxylated compounds. Anal. Chem.72,1352–9 (2000).▪ Excellent paper discussing sample preparation techniques for bioanalysis.
  Medline CASGoogle Scholar
• 30  Chang MS, Ji Q, Zhang J, El-Shourbagy TA. Historical review of sample preparation for chromatographic bioanalysis: pros and cons. Drug Dev. Res.68,107–133 (2007).▪ Discusses the application of mass defect filtering techniques for metabolite detection.
  CASGoogle Scholar
• 31  Zhu M, Ma L, Zhang D et al. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab. Dispos.34,1722–33 (2006).
  Medline CASGoogle Scholar
• 32  Zhu M, Ma L, Zhang H, Humphreys WG. Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. Anal. Chem.79,8333–41 (2007).
  Medline CASGoogle Scholar
• 33  Zhang H, Zhu M, Ray KL, Ma L, Zhang D. Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Commun. Mass Spectrom.22,2082–8 (2008).▪ Discusses the application of background subtraction techniques for metabolite detection.
  Medline CASGoogle Scholar
• 34  Zhu P, Ding W, Tong W, Ghosal A, Alton K, Chowdhury S. A retention-time-shift-tolerant background subtraction and noise reduction algorithm (BgS-NoRA) for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices. Rapid Commun. Mass Spectrom.23,1563–72 (2009).
  Medline CASGoogle Scholar
• 35  Zhang H, Ma L, He K, Zhu M. An algorithm for thorough background subtraction from high-resolution LC–MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. J. Mass Spectrom.43,1191–200 (2008).▪ Excellent review of the detectors in consideration for supporting detection, characterization and quantitation of metabolites in early clinical studies.
  Medline CASGoogle Scholar
• 36  Wright P, Miao Z, Shilliday B. Metabolite quantitation: detector technology and MIST implications. Bioanalyis1(4),831–845 (2009).
  CASGoogle Scholar
• 37  Vishwanathan K, Babalola K, Wang J et al. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol.22,311–322 (2009).
  Medline CASGoogle Scholar
• 38  Vishwanathan K, Babalola K, Wang J et al. Plasma pooling to obtain AUCs of metabolites present in preclinical species: addressing MIST guidance using non-radiolabeled compounds. Presented at: ISSX Meeting. San Diego, CA, USA, October 12-16 (2008).
  Google Scholar
• 39  Cisar P, Nobilis M, Vybiralova Z et al. Disposition study of a new potential antineoplastic agent dimefluron in rats using high-performance liquid chromatography with ultraviolet and mass spectrometric detection. J. Pharm. Biomed. Anal.37,1059–1071 (2005).
  Medline CASGoogle Scholar
• 40  Zhu M, Zhao W, Jimenez H et al. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos.33,500–507 (2005).
  Medline CASGoogle Scholar
• 41  Cai H, Josephs JL, Ramanathan R, Crafts C, Bailey BA, Humphreys WG. A novel detection technology: charged aerosol detection coupled with HPLC, UV and LTQ-orbitrap MS for drug metabolism studies. Presented at: 58th ASMS Conference on Mass Spectrometry and Allied Topics, Salt Lake City, UT, USA, May 23-27, (2010)
  Google Scholar
• 42  Zhang B, Li X, Yan B. Advances in HPLC Detection – towards universal detection. Anal. Bioanal. Chem.390,299–301 (2008).
  Medline CASGoogle Scholar
• 43  Zhang D, Raghavan N, Chando T et al. LC–MS/MS-based approach for obtaining exposue estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Drug Metab. Lett.1,293–298 (2007).
  Medline CASGoogle Scholar
• 44  Yu C, Chen CL, Gorycki FL, Neiss TG. A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection. Rapid Commun. Mass Spectrom.21,497–502 (2007).
  Medline CASGoogle Scholar
• 45  Espina R, Yu L, Wang J et al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol.22,299–310 (2009).▪ Excellent presentations of the application of captive spray ionization-MS.
  Medline CASGoogle Scholar
• 46  Nugent K, Zhu Y, Kent P, Phinney B, Alvarado R. CaptiveSpray: a new ionization technique to maximizing speed, sensitivity, resolution and robustness for LC–MS protein biomarker quantitation. Presented at: 57th ASMS Conference on Mass Spectrometry and Allied Topics, Philadelphia, PA, USA, May 31-June 4, (2009)
  Google Scholar
• 47  Raghavan N, Ramanathan R, Comezoglu SN, Humphreys WG. LC–captivespray ionization-mass spectrometry for detection, characterization and quantification of circulating human metabolites. Presented at: 58th ASMS Conference on Mass Spectrometry and Allied Topics, Salt Lake City, UT, USA, May 23-27, (2010)
  Google Scholar
• 48  Penner N, Ramanathan R, Zgoda-Pols J, Chowdhury S. Quantitative determination of hippuric and benzoic acids in urine by LC–MS/MS using surrogate standards. J. Pharm. Biomed. Anal.52,534–543 (2010).
  Medline CASGoogle Scholar
• 49  Korfmacher W. Bioanalytical assays in a drug discovery environment. In Using Mass Spectrometry for Drug Metabolism Studies. Korfmacher W (Ed). CRC Press, Boca Raton, FL, USA, 1–34, (2005).
  Google Scholar
• 50  Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res.24,1962–1973 (2007).
  Medline CASGoogle Scholar
• 51  Shah VP. The history of bioanalytical method validation and regulation: evolution of a guidance document on bioanalytical methods validation. AAPS J.9,E43–E47 (2007).
  CASGoogle Scholar
• 52  Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J.9,E109–14 (2007).
  Medline CASGoogle Scholar
• 53  Baillie TA, Cayen MN, Fouda H et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol.182,188–196 (2002).
  Medline CASGoogle Scholar
• 54  Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, Osterberg RE. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol.190,91–2; (Author reply) 93–94 (2003).
  Medline CASGoogle Scholar
• 55  Smith DA, Obach RS. Seeing through the MIST: abundance versus percentage. commentary on metabolites in safety testing. Drug Metab. Dispos.33,1409–1417 (2005).
  Medline CASGoogle Scholar
• 56  Prueksaritanont T, Lin JH, Baillie TA. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol.217,143–152 (2006).
  Medline CASGoogle Scholar
• 57  Robison, TW and Jacobs, A. Metabolite in safety testing. Bioanalysis, 1(7),1193–1200 (2009).
  CASGoogle Scholar
• 101  US Food and Drug Administration. Guidance for Industry: Safety Testing of Drug Metabolites (2008) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf
  Google Scholar
• 102  International Conference of Harmonization. Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (2010) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf
  Google Scholar
• 103  US Food and Drug Administration. Guidance for Industry: Safety Testing of Drug Metabolites Draft Guidance (2005) www.fda.gov/ohrms/dockets/98fr/2005d-0203-gdl0001.pdf
  Google Scholar